1
|
Stokkevåg CH, Journy N, Vogelius IR, Howell RM, Hodgson D, Bentzen SM. Radiation Therapy Technology Advances and Mitigation of Subsequent Neoplasms in Childhood Cancer Survivors. Int J Radiat Oncol Biol Phys 2024; 119:681-696. [PMID: 38430101 DOI: 10.1016/j.ijrobp.2024.01.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 12/17/2023] [Accepted: 01/13/2024] [Indexed: 03/03/2024]
Abstract
PURPOSE In this Pediatric Normal Tissue Effects in the Clinic (PENTEC) vision paper, challenges and opportunities in the assessment of subsequent neoplasms (SNs) from radiation therapy (RT) are presented and discussed in the context of technology advancement. METHODS AND MATERIALS The paper discusses the current knowledge of SN risks associated with historic, contemporary, and future RT technologies. Opportunities for research and SN mitigation strategies in pediatric patients with cancer are reviewed. RESULTS Present experience with radiation carcinogenesis is from populations exposed during widely different scenarios. Knowledge gaps exist within clinical cohorts and follow-up; dose-response and volume effects; dose-rate and fractionation effects; radiation quality and proton/particle therapy; age considerations; susceptibility of specific tissues; and risks related to genetic predisposition. The biological mechanisms associated with local and patient-level risks are largely unknown. CONCLUSIONS Future cancer care is expected to involve several available RT technologies, necessitating evidence and strategies to assess the performance of competing treatments. It is essential to maximize the utilization of existing follow-up while planning for prospective data collection, including standardized registration of individual treatment information with linkage across patient databases.
Collapse
Affiliation(s)
- Camilla H Stokkevåg
- Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway; Department of Physics and Technology, University of Bergen, Bergen, Norway.
| | - Neige Journy
- French National Institute of Health and Medical Research (INSERM) Unit 1018, Centre for Research in Epidemiology and Population Health, Paris Saclay University, Gustave Roussy, Villejuif, France
| | - Ivan R Vogelius
- Department of Clinical Oncology, Centre for Cancer and Organ Diseases and University of Copenhagen, Copenhagen, Denmark
| | - Rebecca M Howell
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas
| | - David Hodgson
- Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Center, Toronto, Ontario, Canada
| | - Søren M Bentzen
- Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland
| |
Collapse
|
2
|
Tzanis E, Mazonakis M, Damilakis J. A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses. Rep Pract Oncol Radiother 2022; 27:170-175. [PMID: 35402031 PMCID: PMC8989449 DOI: 10.5603/rpor.a2022.0014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Accepted: 01/16/2022] [Indexed: 11/25/2022] Open
Abstract
The aim of this study was the development of a software tool (SCRcalc) for the automatic estimation of the patient- and organ-specific cancer risk due to radiotherapy. SCRcalc was developed using the Python 3.8.7 programming language. It incorporates equations and parameters of mechanistic models for the calculation of the organ equivalent dose (OED), the excess absolute risk (EA R) and the lifetime attributable risk (LA R) of carcinogenesis for various organs due to radiotherapy. Data from differential dose-volume histograms, as defined by a treatment planning system, could be automatically inserted into the program. Eighteen different cancer risk estimates for various organs were performed of patients subjected to radiation therapy with conventional and modulated techniques. These software estimates were compared with manual calculations. SCRcalc was developed as a standalone executable program without any dependencies. It enables direct estimations of the OED and LAR for various organs at risk. An important aspect of the software is that it does not require pre-processing of the DVH data. No differences were found between the SCRcalc results and those derived from manual calculations. The newly developed software offers the possibility to medical physicists and radiation oncologists to directly estimate the probability of radiotherapy-induced secondary malignancies for various organs at risk.
Collapse
Affiliation(s)
- Eleftherios Tzanis
- Department of Medical Physics, Medical School, University of Crete, Heraklion, Crete, Greece
| | - Michael Mazonakis
- Department of Medical Physics, Medical School, University of Crete, Heraklion, Crete, Greece
| | - John Damilakis
- Department of Medical Physics, Medical School, University of Crete, Heraklion, Crete, Greece
| |
Collapse
|
3
|
Treutwein M, Loeschel R, Hipp M, Koelbl O, Dobler B. Secondary malignancy risk for patients with localized prostate cancer after intensity-modulated radiotherapy with and without flattening filter. J Appl Clin Med Phys 2020; 21:197-205. [PMID: 33147377 PMCID: PMC7769399 DOI: 10.1002/acm2.13088] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Revised: 09/16/2020] [Accepted: 07/24/2020] [Indexed: 12/20/2022] Open
Abstract
Men treated for localized prostate cancer by radiotherapy have often a remaining life span of 10 yr or more. Therefore, the risk for secondary malignancies should be taken into account. Plans for ten patients were evaluated which had been performed on an Oncentra® treatment planning system for a treatment with an Elekta Synergy™ linac with Agility™ head. The investigated techniques involved IMRT and VMTA with and without flattening filter. Different dose response models were applied for secondary carcinoma and sarcoma risk in the treated region and also in the periphery. As organs at risk we regarded for carcinoma risk urinary bladder, rectum, colon, esophagus, thyroid, and for sarcoma risk bone and soft tissue. The excess absolute risk (EAR) was found very similar in the treated region for both techniques (IMRT and VMAT) and also for both with and without flattening filter. The secondary sarcoma risk resulted about one magnitude smaller than the secondary carcinoma risk. The EAR to the peripheral organs was statistically significant reduced by application of the flattening filter free mode concerning the flattening filter as main source of scattered dose. Application of flattening filter free mode can thus support to reduce second malignancy risk for patients with localized prostate cancer.
Collapse
Affiliation(s)
- Marius Treutwein
- Department for radiotherapy, Regensburg University Medical Center, Regensburg, Germany
| | - Rainer Loeschel
- Faculty of computer science and mathematics, Ostbayerische Technische Hochschule, Regensburg, Germany
| | - Matthias Hipp
- Department for radiotherapy, Regensburg University Medical Center, Regensburg, Germany.,Strahlentherapie, Klinikum St. Marien, Amberg, Germany
| | - Oliver Koelbl
- Department for radiotherapy, Regensburg University Medical Center, Regensburg, Germany
| | - Barbara Dobler
- Department for radiotherapy, Regensburg University Medical Center, Regensburg, Germany
| |
Collapse
|
4
|
Cancer risk after breast proton therapy considering physiological and radiobiological uncertainties. Phys Med 2020; 76:1-6. [PMID: 32563956 DOI: 10.1016/j.ejmp.2020.06.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 06/04/2020] [Accepted: 06/06/2020] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND The reduced normal tissue dose burden from protons can reduce the risk of second cancer for breast cancer patients. Breathing motion and the impact of variable relative biological effectiveness (RBE) are however concerns for proton dose distributions. This study aimed to quantify the impact of these factors on risk predictions from proton and photon therapy. MATERIALS AND METHODS Twelve patients were planned in free breathing with protons and photons to deliver 50 Gy (RBE) in 25 fractions (assuming RBE = 1.1 for protons) to the left breast. Second cancer risk was evaluated with several models for the lungs, contralateral breast, heart and esophagus as organs at risk (OARs). Plans were recalculated on CT-datasets acquired in extreme phases to account for breathing motion. Proton plans were also recalculated assuming variable RBE for a range of radiobiological parameters. RESULTS The OARs received substantially lower doses from protons compared to photons. The highest risks were for the lungs (average second cancer risks of 0.31% and 0.12% from photon and proton plans, respectively). The reduced risk with protons was maintained, even when breathing and/or RBE variation were taken into account. Furthermore, while the total risks from the photon plans were seen to increase with the integral dose, no such correlation was observed for the proton plans. CONCLUSIONS Protons have an advantage over the photons with respect to the induction of cancer. Uncertainties in physiological movements and radiobiological parameters affected the absolute risk estimates, but not the general trend of lower risk associated with proton therapy.
Collapse
|
5
|
Risk of contralateral breast and ipsilateral lung cancer induction from forward-planned IMRT for breast carcinoma. Phys Med 2019; 60:44-49. [DOI: 10.1016/j.ejmp.2019.03.021] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 03/12/2019] [Accepted: 03/20/2019] [Indexed: 01/17/2023] Open
|
6
|
Abstract
For stochastic effects such as cancer, linear-quadratic models of dose are often used to extrapolate from the experience of the Japanese atomic bomb survivors to estimate risks from low doses and low dose rates. The low dose extrapolation factor (LDEF), which consists of the ratio of the low dose slope (as derived via fitting a linear-quadratic model) to the slope of the straight line fitted to a specific dose range, is used to derive the degree of overestimation (if LDEF > 1) or underestimation (if LDEF < 1) of low dose risk by linear extrapolation from effects at higher doses. Likewise, a dose rate extrapolation factor (DREF) can be defined, consisting of the ratio of the low dose slopes at high and low dose rates. This paper reviews a variety of human and animal data for cancer and non-cancer endpoints to assess evidence for curvature in the dose response (i.e. LDEF) and modifications of the dose response by dose rate (i.e. DREF). The JANUS mouse data imply that LDEF is approximately 0.2-0.8 and DREF is approximately 1.2-2.3 for many tumours following gamma exposure, with corresponding figures of approximately 0.1-0.9 and 0.0-0.2 following neutron exposure. This paper also cursorily reviews human data which allow direct estimates of low dose and low dose rate risk.
Collapse
Affiliation(s)
- M P Little
- Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-9778, USA
| |
Collapse
|
7
|
Mazonakis M, Tzedakis A, Lyraraki E, Damilakis J. Risk of developing radiogenic cancer following photon-beam radiotherapy for Graves' orbitopathy. Med Phys 2018; 45:4775-4782. [PMID: 30105825 DOI: 10.1002/mp.13130] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Revised: 08/07/2018] [Accepted: 08/07/2018] [Indexed: 11/09/2022] Open
Abstract
PURPOSE The objective of this study was to estimate the probability for cancer development due to radiotherapy for Graves' orbitopathy with 6 MV x rays. METHODS Orbital irradiation was simulated with the MCNP code. The radiation dose received by 10 out-of-field organs having a strong disposition for carcinogenesis was calculated with Monte Carlo methods. These dose calculations were used to estimate the organ-dependent lifetime attributable risk (LAR) for cancer induction in 30- and 50-yr-old males and females on the basis of the linear model suggested by the BEIR-VII report. Differential dose-volume histograms derived from patients' three-dimensional (3D) radiotherapy plans were employed to determine the organ equivalent dose (OED) of the brain which was partly exposed to primary radiation. The OED and the relevant LAR for brain cancer development were assessed with the plateau, bell-shaped and mechanistic models. The radiotherapy-induced cancer risks were compared with the lifetime intrinsic risk (LIR) values for unexposed population. RESULTS The radiation dose range to organs excluded from the treatment volume was 0.1-91.0 mGy for a target dose of 20 Gy. These peripheral organ doses increased the LIRs for cancer development of unexposed 30- and 50-yr-old males up to 1.0% and 0.2%, respectively. The corresponding elevations after radiotherapy of females were 2.0% and 0.4%. The use of nonlinear models gave an OED range of the brain of 482.0-562.5 mGy depending upon the model used for analysis and the patient's gender. The elevation of the LIR for developing brain malignancies after radiotherapy of 30-yr-old males and females reached to 13.3% and 16.6%, respectively. The corresponding increases after orbital irradiation at the age of 50 yr were 6.7% and 8.3%. CONCLUSIONS The level of the LIR increase attributable to radiation therapy for GO varied widely by the organ under examination and the age and gender of the exposed subject. This study provides the required data to quantify the elevation of these baseline cancer risks following orbital irradiation.
Collapse
Affiliation(s)
- Michalis Mazonakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, P.O. Box 2208, 71003, Iraklion, Crete, Greece
| | - Antonis Tzedakis
- Department of Medical Physics, University Hospital of Iraklion, 71110, Iraklion, Crete, Greece
| | - Efrossyni Lyraraki
- Department of Radiotherapy and Oncology, University Hospital of Iraklion, 71110, Iraklion, Crete, Greece
| | - John Damilakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, P.O. Box 2208, 71003, Iraklion, Crete, Greece
| |
Collapse
|
8
|
Tran V, Little MP. Dose and dose rate extrapolation factors for malignant and non-malignant health endpoints after exposure to gamma and neutron radiation. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2017; 56:299-328. [PMID: 28939964 DOI: 10.1007/s00411-017-0707-4] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Accepted: 08/06/2017] [Indexed: 06/07/2023]
Abstract
Murine experiments were conducted at the JANUS reactor in Argonne National Laboratory from 1970 to 1992 to study the effect of acute and protracted radiation dose from gamma rays and fission neutron whole body exposure. The present study reports the reanalysis of the JANUS data on 36,718 mice, of which 16,973 mice were irradiated with neutrons, 13,638 were irradiated with gamma rays, and 6107 were controls. Mice were mostly Mus musculus, but one experiment used Peromyscus leucopus. For both types of radiation exposure, a Cox proportional hazards model was used, using age as timescale, and stratifying on sex and experiment. The optimal model was one with linear and quadratic terms in cumulative lagged dose, with adjustments to both linear and quadratic dose terms for low-dose rate irradiation (<5 mGy/h) and with adjustments to the dose for age at exposure and sex. After gamma ray exposure there is significant non-linearity (generally with upward curvature) for all tumours, lymphoreticular, respiratory, connective tissue and gastrointestinal tumours, also for all non-tumour, other non-tumour, non-malignant pulmonary and non-malignant renal diseases (p < 0.001). Associated with this the low-dose extrapolation factor, measuring the overestimation in low-dose risk resulting from linear extrapolation is significantly elevated for lymphoreticular tumours 1.16 (95% CI 1.06, 1.31), elevated also for a number of non-malignant endpoints, specifically all non-tumour diseases, 1.63 (95% CI 1.43, 2.00), non-malignant pulmonary disease, 1.70 (95% CI 1.17, 2.76) and other non-tumour diseases, 1.47 (95% CI 1.29, 1.82). However, for a rather larger group of malignant endpoints the low-dose extrapolation factor is significantly less than 1 (implying downward curvature), with central estimates generally ranging from 0.2 to 0.8, in particular for tumours of the respiratory system, vasculature, ovary, kidney/urinary bladder and testis. For neutron exposure most endpoints, malignant and non-malignant, show downward curvature in the dose response, and for most endpoints this is statistically significant (p < 0.05). Associated with this, the low-dose extrapolation factor associated with neutron exposure is generally statistically significantly less than 1 for most malignant and non-malignant endpoints, with central estimates mostly in the range 0.1-0.9. In contrast to the situation at higher dose rates, there are statistically non-significant decreases of risk per unit dose at gamma dose rates of less than or equal to 5 mGy/h for most malignant endpoints, and generally non-significant increases in risk per unit dose at gamma dose rates ≤5 mGy/h for most non-malignant endpoints. Associated with this, the dose-rate extrapolation factor, the ratio of high dose-rate to low dose-rate (≤5 mGy/h) gamma dose response slopes, for many tumour sites is in the range 1.2-2.3, albeit not statistically significantly elevated from 1, while for most non-malignant endpoints the gamma dose-rate extrapolation factor is less than 1, with most estimates in the range 0.2-0.8. After neutron exposure there are non-significant indications of lower risk per unit dose at dose rates ≤5 mGy/h compared to higher dose rates for most malignant endpoints, and for all tumours (p = 0.001), and respiratory tumours (p = 0.007) this reduction is conventionally statistically significant; for most non-malignant outcomes risks per unit dose non-significantly increase at lower dose rates. Associated with this, the neutron dose-rate extrapolation factor is less than 1 for most malignant and non-malignant endpoints, in many cases statistically significantly so, with central estimates mostly in the range 0.0-0.2.
Collapse
Affiliation(s)
- Van Tran
- Radiation Epidemiology Branch, National Cancer Institute, Medical Center Drive 9609, MSC 9778, Rockville, MD, 20892-9778, USA
| | - Mark P Little
- Radiation Epidemiology Branch, National Cancer Institute, Medical Center Drive 9609, MSC 9778, Rockville, MD, 20892-9778, USA.
| |
Collapse
|
9
|
Dasu A, Toma-Dasu I. Models for the risk of secondary cancers from radiation therapy. Phys Med 2017; 42:232-238. [DOI: 10.1016/j.ejmp.2017.02.015] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Revised: 02/10/2017] [Accepted: 02/15/2017] [Indexed: 11/25/2022] Open
|
10
|
The risk of second primary cancers due to peripheral photon and neutron doses received during prostate cancer external beam radiation therapy. Phys Med 2017; 42:253-258. [DOI: 10.1016/j.ejmp.2017.02.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Revised: 02/20/2017] [Accepted: 02/20/2017] [Indexed: 11/18/2022] Open
|
11
|
Mavroidis P, Komisopoulos G, Buckey C, Mavroeidi M, Swanson GP, Baltas D, Papanikolaou N, Stathakis S. Radiobiological evaluation of prostate cancer IMRT and conformal-RT plans using different treatment protocols. Phys Med 2017; 40:33-41. [DOI: 10.1016/j.ejmp.2017.07.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Revised: 06/07/2017] [Accepted: 07/04/2017] [Indexed: 10/19/2022] Open
|
12
|
Mazonakis M, Damilakis J. Cancer risk after radiotherapy for benign diseases. Phys Med 2017; 42:285-291. [PMID: 28189418 DOI: 10.1016/j.ejmp.2017.01.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Revised: 12/28/2016] [Accepted: 01/19/2017] [Indexed: 11/16/2022] Open
Abstract
Radiotherapy with low to intermediate doses has been historically employed for the management of several benign diseases. The exposure to ionizing radiation may increase the probability for carcinogenesis. The knowledge of this probability is of value for weighting the benefits and risks of radiotherapy against different therapeutic approaches. This study initially reviews the epidemiologic data associated with the cancer induction due to radiotherapy for non-malignant conditions in previous decades. Most of these data were derived from patients irradiated with conventional techniques, which are no longer applied, for some benign diseases not treated with radiotherapy nowadays. The follow-up of a series of patients undergoing modern radiotherapy for benign disorders may be used for estimating the radiation-induced cancer risk. The realization of this process is often difficult due to the relatively small number of patients undergoing radiation therapy for such diseases in many countries and due to long latent period for the appearance of a malignancy after exposure. The combination of dosimetric data, which can be obtained by phantom measurements or treatment planning systems or Monte Carlo calculations, with the appropriate linear and non-linear risk models may lead to theoretical estimates of the radiotherapy-induced cancer risks. The limitations of the method providing a whole-body cancer risk based on the effective dose concept are presented. The theoretical organ-specific risks for carcinogenesis give useful information about the development of malignancies at any in-field, partially in-field and out-of-field critical site. The uncertainties of the organ-dependent cancer risk estimates are discussed.
Collapse
Affiliation(s)
- M Mazonakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, P.O. Box 2208, 71003 Iraklion, Crete, Greece
| | - J Damilakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, P.O. Box 2208, 71003 Iraklion, Crete, Greece.
| |
Collapse
|
13
|
Mazonakis M, Tzedakis A, Lyraraki E, Damilakis J. Organ-specific radiation-induced cancer risk estimates due to radiotherapy for benign pigmented villonodular synovitis. Phys Med Biol 2016; 61:6400-12. [DOI: 10.1088/0031-9155/61/17/6400] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
14
|
Stokkevåg CH, Fukahori M, Nomiya T, Matsufuji N, Engeseth GM, Hysing LB, Ytre-Hauge KS, Rørvik E, Szostak A, Muren LP. Modelling of organ-specific radiation-induced secondary cancer risks following particle therapy. Radiother Oncol 2016; 120:300-6. [PMID: 27424291 DOI: 10.1016/j.radonc.2016.07.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2015] [Revised: 06/20/2016] [Accepted: 07/03/2016] [Indexed: 01/17/2023]
Abstract
BACKGROUND AND PURPOSE Radiation-induced cancer is a serious late effect that may follow radiotherapy. A considerable uncertainty is associated with carcinogenesis from photon-based treatment, and even less established when including relative biological effectiveness (RBE) for particle therapy. The aim of this work was therefore to estimate and in particular explore relative risks (RR) of secondary cancer (SC) following particle therapy as applied in treatment of prostate cancer. MATERIAL AND METHODS RRs of radiation-induced SC in the bladder and rectum were estimated using a bell-shaped dose-response model incorporating RBE and fractionation effects. The risks from volumetric modulated arc therapy (VMAT) were compared to intensity-modulated proton therapy (IMPT) and scanning carbon ions for ten patients. RESULTS The mean estimated RR (95% CI) of SC for VMAT/C-ion was 1.31 (0.65-2.18) for the bladder and 0.58 (0.41-0.80) for the rectum. Corresponding values for VMAT/IMPT were 1.72 (1.06-2.37) and 1.10 (0.78-1.43). The radio-sensitivity parameter α had the strongest influence on the results with decreasing RR for increasing values of α. CONCLUSION Based on the wide spread in RR between patients and variations across the included parameter values, the risk profiles of the rectum and bladder were not dramatically different for the investigated radiotherapy techniques.
Collapse
Affiliation(s)
- Camilla H Stokkevåg
- Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway; Department of Physics and Technology, University of Bergen, Norway.
| | - Mai Fukahori
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
| | - Takuma Nomiya
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan; Department of Radiation Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Naruhiro Matsufuji
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
| | - Grete May Engeseth
- Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
| | - Liv B Hysing
- Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
| | | | - Eivind Rørvik
- Department of Physics and Technology, University of Bergen, Norway
| | - Artur Szostak
- Department of Physics and Technology, University of Bergen, Norway
| | - Ludvig P Muren
- Department of Medical Physics, Aarhus University/Aarhus University Hospital, Denmark
| |
Collapse
|
15
|
Stokkevåg CH, Engeseth GM, Hysing LB, Ytre-Hauge KS, Ekanger C, Muren LP. Risk of radiation-induced secondary rectal and bladder cancer following radiotherapy of prostate cancer. Acta Oncol 2015; 54:1317-25. [PMID: 26230629 DOI: 10.3109/0284186x.2015.1061691] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND An elevated risk of radiation-induced secondary cancer (SC) has been observed in prostate cancer patients after radiotherapy (RT), rising to as high as one in 70 patients with more than 10 years follow-up. In this study we have estimated SC risks following RT with both previous and contemporary techniques, including proton therapy, using risk models based on different dose-response relationships. MATERIAL AND METHODS RT plans treating the prostate and seminal vesicles with either conformal radiotherapy (CRT), volumetric modulated arc therapy (VMAT) or intensity-modulated proton therapy (IMPT) were created for 10 patients. The risks of radiation-induced cancer were estimated for the bladder and rectum using dose-response models reflecting varying degrees of cell sterilisation: a linear model, a linear-plateau model and a bell-shaped model also accounting for fractionated RT. RESULTS The choice of risk models was found to rank the plans quite differently, with the CRT plans having the lowest SC risk using the bell-shaped model, while resulting in the highest risk applying the linear model. Considering all dose-response scenarios, median relative risks of VMAT versus IMPT were 1.1-1.7 for the bladder and 0.9-1.8 for the rectum. Risks of radiation-induced bladder and rectal cancers were lower from VMAT if exposed at 80 years versus IMPT if exposed at 50 years. CONCLUSIONS The SC risk estimations for the bladder and rectum revealed no clear relative relationship between the contemporary techniques and CRT, with divergent results depending on choice of model. However, the SC risks for these organs when using IMPT were lower or comparable to VMAT. SC risks could be assessed when considering referral of prostate cancer patients to proton therapy, taking also general patient characteristics, such as age, into account.
Collapse
Affiliation(s)
- Camilla H Stokkevåg
- a Department of Oncology and Medical Physics , Haukeland University Hospital , Bergen , Norway
- b Department of Physics and Technology , University of Bergen , Bergen , Norway
| | - Grete M Engeseth
- a Department of Oncology and Medical Physics , Haukeland University Hospital , Bergen , Norway
| | - Liv B Hysing
- a Department of Oncology and Medical Physics , Haukeland University Hospital , Bergen , Norway
| | | | - Christian Ekanger
- a Department of Oncology and Medical Physics , Haukeland University Hospital , Bergen , Norway
| | - Ludvig P Muren
- c Department of Medical Physics , Aarhus University/Aarhus University Hospital , Aarhus , Denmark
| |
Collapse
|
16
|
Schneider U, Walsh L. Age at exposure and attained age variations of cancer risk in the Japanese A-bomb and radiotherapy cohorts. Med Phys 2015; 42:4755-61. [DOI: 10.1118/1.4927062] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
17
|
Komisopoulos G, Mavroidis P, Rodriguez S, Stathakis S, Papanikolaou N, Nikiforidis GC, Sakellaropoulos GC. Radiobiologic comparison of helical tomotherapy, intensity modulated radiotherapy, and conformal radiotherapy in treating lung cancer accounting for secondary malignancy risks. Med Dosim 2014; 39:337-47. [DOI: 10.1016/j.meddos.2014.06.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2013] [Revised: 05/31/2014] [Accepted: 06/12/2014] [Indexed: 12/25/2022]
|
18
|
Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J. Second primary cancers after radiation for prostate cancer: a review of data from planning studies. Radiat Oncol 2013; 8:172. [PMID: 23835163 PMCID: PMC3724744 DOI: 10.1186/1748-717x-8-172] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2013] [Accepted: 06/23/2013] [Indexed: 11/29/2022] Open
Abstract
A review of planning studies was undertaken to evaluate estimated risks of radiation induced second primary cancers (RISPC) associated with different prostate radiotherapy techniques for localised prostate cancer. A total of 83 publications were identified which employed a variety of methods to estimate RISPC risk. Of these, the 16 planning studies which specifically addressed absolute or relative second cancer risk using dose-response models were selected for inclusion within this review. There are uncertainties and limitations related to all the different methods for estimating RISPC risk. Whether or not dose models include the effects of the primary radiation beam, as well as out-of-field regions, influences estimated risks. Regarding the impact of IMRT compared to 3D-CRT, at equivalent energies, several studies suggest an increase in risk related to increased leakage contributing to out-of-field RISPC risk, although in absolute terms this increase in risk may be very small. IMRT also results in increased low dose normal tissue irradiation, but the extent to which this has been estimated to contribute to RISPC risk is variable, and may also be very small. IMRT is often delivered using 6MV photons while conventional radiotherapy often requires higher energies to achieve adequate tissue penetration, and so comparisons between IMRT and older techniques should not be restricted to equivalent energies. Proton and brachytherapy planning studies suggest very low RISPC risks associated with these techniques. Until there is sufficient clinical evidence regarding RISPC risks associated with modern irradiation techniques, the data produced from planning studies is relevant when considering which patients to irradiate, and which technique to employ.
Collapse
Affiliation(s)
- Louise Murray
- St James’s Institute of Oncology, Beckett St, Leeds LS9 7TF, UK
- University of Leeds, Leeds, UK
| | - Ann Henry
- St James’s Institute of Oncology, Beckett St, Leeds LS9 7TF, UK
- University of Leeds, Leeds, UK
| | - Peter Hoskin
- Mount Vernon Cancer Centre, Northwood, London, UK
| | | | | |
Collapse
|
19
|
Rechner LA, Howell RM, Zhang R, Etzel C, Lee AK, Newhauser WD. Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer. Phys Med Biol 2012; 57:7117-32. [PMID: 23051714 DOI: 10.1088/0031-9155/57/21/7117] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Prostate cancer patients who undergo radiotherapy are at an increased risk to develop a radiogenic second cancer. Proton therapy has been shown to reduce the predicted risk of second cancer when compared to intensity modulated radiotherapy. However, it is unknown if this is also true for the rotational therapies proton arc therapy and volumetric modulated arc therapy (VMAT). The objective of this study was to compare the predicted risk of cancer following proton arc therapy and VMAT for prostate cancer. Proton arc therapy and VMAT plans were created for three patients. Various risk models were combined with the dosimetric data (therapeutic and stray dose) to predict the excess relative risk (ERR) of cancer in the bladder and rectum. Ratios of ERR values (RRR) from proton arc therapy and VMAT were calculated. RRR values ranged from 0.74 to 0.99, and all RRR values were shown to be statistically less than 1, except for the value calculated with the linear-non-threshold risk model. We conclude that the predicted risk of cancer in the bladder or rectum following proton arc therapy for prostate cancer is either less than or approximately equal to the risk following VMAT, depending on which risk model is applied.
Collapse
Affiliation(s)
- Laura A Rechner
- Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| | | | | | | | | | | |
Collapse
|
20
|
Paganetti H, Athar BS, Moteabbed M, A Adams J, Schneider U, Yock TI. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field. Phys Med Biol 2012; 57:6047-61. [DOI: 10.1088/0031-9155/57/19/6047] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
21
|
Zurl B, Stranzl H, Winkler P, Kapp KS. Quantification of contralateral breast dose and risk estimate of radiation-induced contralateral breast cancer among young women using tangential fields and different modes of breathing. Int J Radiat Oncol Biol Phys 2012; 85:500-5. [PMID: 22633190 DOI: 10.1016/j.ijrobp.2012.04.016] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2011] [Revised: 04/05/2012] [Accepted: 04/10/2012] [Indexed: 10/27/2022]
Abstract
PURPOSE Whole breast irradiation with deep-inspiration breath-hold (DIBH) technique among left-sided breast cancer patients significantly reduces cardiac irradiation; however, a potential disadvantage is increased incidental irradiation of the contralateral breast. METHODS AND MATERIALS Contralateral breast dose (CBD) was calculated by comparing 400 treatment plans of 200 left-sided breast cancer patients whose tangential fields had been planned on gated and nongated CT data sets. Various anatomic and field parameters were analyzed for their impact on CBD. For a subgroup of patients (aged ≤45 years) second cancer risk in the contralateral breast (CB) was modeled by applying the linear quadratic model, compound models, and compound models considering dose-volume information (DVH). RESULTS The mean CBD was significantly higher in DIBH with 0.69 Gy compared with 0.65 Gy in normal breathing (P=.01). The greatest impact on CBD was due to a shift of the inner field margin toward the CB in DIBH (mean 0.4 cm; range, 0-2), followed by field size in magnitude. Calculation with different risk models for CBC revealed values of excess relative risk/Gy ranging from 0.48-0.65 vs 0.46-0.61 for DIBH vs normal breathing, respectively. CONCLUSION Contralateral breast dose, although within a low dose range, was mildly but significantly increased in 200 treatment plans generated under gated conditions, predominately due to a shift in the medial field margin. Risk modeling for CBC among women aged ≤45 years also pointed to a higher risk when comparing DIBH with normal breathing. This risk, however, was substantially lower in the model considering DVH information. We think that clinical decisions should not be affected by this small increase in CBD with DIBH because DIBH is effective in reducing the dose to the heart in all patients.
Collapse
Affiliation(s)
- Brigitte Zurl
- Department of Therapeutic Radiology and Oncology, Medical University of Graz, Austria.
| | | | | | | |
Collapse
|
22
|
Breast cancer and funnel chest. Strahlenther Onkol 2012; 188:127-35. [DOI: 10.1007/s00066-011-0022-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2011] [Accepted: 10/04/2011] [Indexed: 02/02/2023]
|
23
|
Schneider U. Modeling the risk of secondary malignancies after radiotherapy. Genes (Basel) 2011; 2:1033-49. [PMID: 24710304 PMCID: PMC3927608 DOI: 10.3390/genes2041033] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2011] [Revised: 11/01/2011] [Accepted: 11/04/2011] [Indexed: 12/16/2022] Open
Abstract
In developed countries, more than half of all cancer patients receive radiotherapy at some stage in the management of their disease. However, a radiation-induced secondary malignancy can be the price of success if the primary cancer is cured or at least controlled. Therefore, there is increasing concern regarding radiation-related second cancer risks in long-term radiotherapy survivors and a corresponding need to be able to predict cancer risks at high radiation doses. Of particular interest are second cancer risk estimates for new radiation treatment modalities such as intensity modulated radiotherapy, intensity modulated arc-therapy, proton and heavy ion radiotherapy. The long term risks from such modern radiotherapy treatment techniques have not yet been determined and are unlikely to become apparent for many years, due to the long latency time for solid tumor induction. Most information on the dose-response of radiation-induced cancer is derived from data on the A-bomb survivors who were exposed to γ-rays and neutrons. Since, for radiation protection purposes, the dose span of main interest is between zero and one Gy, the analysis of the A-bomb survivors is usually focused on this range. With increasing cure rates, estimates of cancer risk for doses larger than one Gy are becoming more important for radiotherapy patients. Therefore in this review, emphasis was placed on doses relevant for radiotherapy with respect to radiation induced solid cancer. Simple radiation protection models should be used only with extreme care for risk estimates in radiotherapy, since they are developed exclusively for low dose. When applied to scatter radiation, such models can predict only a fraction of observed second malignancies. Better semi-empirical models include the effect of dose fractionation and represent the dose-response relationships more accurately. The involved uncertainties are still huge for most of the organs and tissues. A major reason for this is that the underlying processes of the induction of carcinoma and sarcoma are not well known. Most uncertainties are related to the time patterns of cancer induction, the population specific dependencies and to the organ specific cancer induction rates. For radiotherapy treatment plan optimization these factors are irrelevant, as a treatment plan comparison is performed for a patient of specific age, sex, etc. If a treatment plan is compared relative to another one only the shape of the dose-response curve (the so called risk-equivalent dose) is of importance and errors can be minimized.
Collapse
Affiliation(s)
- Uwe Schneider
- Vetsuisse Faculty, University of Zürich, Zürich 8057, Switzerland.
| |
Collapse
|
24
|
Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model 2011; 8:27. [PMID: 21791103 PMCID: PMC3161945 DOI: 10.1186/1742-4682-8-27] [Citation(s) in RCA: 130] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2011] [Accepted: 07/26/2011] [Indexed: 01/29/2023] Open
Abstract
Background and Purpose Most information on the dose-response of radiation-induced cancer is derived from data on the A-bomb survivors. Since, for radiation protection purposes, the dose span of main interest is between zero and one Gy, the analysis of the A-bomb survivors is usually focused on this range. However, estimates of cancer risk for doses larger than one Gy are becoming more important for radiotherapy patients. Therefore in this work, emphasis is placed on doses relevant for radiotherapy with respect to radiation induced solid cancer. Materials and methods For various organs and tissues the analysis of cancer induction was extended by an attempted combination of the linear-no-threshold model from the A-bomb survivors in the low dose range and the cancer risk data of patients receiving radiotherapy for Hodgkin's disease in the high dose range. The data were fitted using organ equivalent dose (OED) calculated for a group of different dose-response models including a linear model, a model including fractionation, a bell-shaped model and a plateau-dose-response relationship. Results The quality of the applied fits shows that the linear model fits best colon, cervix and skin. All other organs are best fitted by the model including fractionation indicating that the repopulation/repair ability of tissue is neither 0 nor 100% but somewhere in between. Bone and soft tissue sarcoma were fitted well by all the models. In the low dose range beyond 1 Gy sarcoma risk is negligible. For increasing dose, sarcoma risk increases rapidly and reaches a plateau at around 30 Gy. Conclusions In this work OED for various organs was calculated for a linear, a bell-shaped, a plateau and a mixture between a bell-shaped and plateau dose-response relationship for typical treatment plans of Hodgkin's disease patients. The model parameters (α and R) were obtained by a fit of the dose-response relationships to these OED data and to the A-bomb survivors. For any three-dimensional inhomogenous dose distribution, cancer risk can be compared by computing OED using the coefficients obtained in this work.
Collapse
Affiliation(s)
- Uwe Schneider
- Radiotherapy Hirslanden AG, Institute for Radiotherapy, Rain 34, 5001 Aarau, Switzerland.
| | | | | |
Collapse
|
25
|
Daşu A, Toma-Daşu I, Franzén L, Widmark A, Nilsson P. Secondary Malignancies From Prostate Cancer Radiation Treatment: A Risk Analysis of the Influence of Target Margins and Fractionation Patterns. Int J Radiat Oncol Biol Phys 2011; 79:738-46. [DOI: 10.1016/j.ijrobp.2009.12.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2009] [Revised: 11/27/2009] [Accepted: 12/01/2009] [Indexed: 12/31/2022]
|
26
|
Johansen S, Danielsen T, Rune Olsen D. Estimated risk for secondary cancer in the contra-lateral breast following radiation therapy of breast cancer. Acta Oncol 2009; 47:391-6. [PMID: 18348001 DOI: 10.1080/02841860701846152] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
PURPOSE To facilitate a discussion about the impact of dose heterogeneity on the risk for secondary contralateral breast (CB) cancer predicted with linear and non linear models associated with primary breast irradiation. METHODS AND MATERIALS Dose volume statistics of the CB calculated for eight patients using a collapsed cone algorithm were used to predict the excess relative risk (ERR) for cancer induction in CB. Both linear and non-linear models were employed. A sensitivity analysis demonstrating the impact of different parameter values on calculated ERR for the eight patients was also included in this study. RESULTS A proportionality assumption was established to make the calculations with a linear and non-linear model comparable. ERR of secondary cancer predicted by the linear model varied considerably between the patients, while the predicted ERR for the same patients using the non-linear model showed very small variation. The predicted ERRs by the two models were indistinguishable for small doses, i.e. below approximately 3 Gy. The sensitivity analysis showed that the quadratic component of the radiation-induction pre-malignant cell term is negligible for lower dose level. The ERR is highly sensitive to the value of alpha(1) and alpha(2). CONCLUSIONS Optimization of breast cancer radiation therapy, where also the risk for radiation induced secondary malignancies in the contralateral breast is taken into account, requires robust and valid risk assessment. The linear dose-risk model does not account for the complexity in the mechanisms underlying the development of secondary malignancies following exposure to radiation; this is particularly important when estimating risk associated with highly heterogeneous dose distributions as is the case in the contralateral breast of women receiving breast cancer irradiation.
Collapse
|
27
|
Schneider U. Mechanistic model of radiation-induced cancer after fractionated radiotherapy using the linear-quadratic formula. Med Phys 2009; 36:1138-43. [DOI: 10.1118/1.3089792] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
28
|
Hillbrand M, Georg D, Gadner H, Pötter R, Dieckmann K. Abdominal cancer during early childhood: a dosimetric comparison of proton beams to standard and advanced photon radiotherapy. Radiother Oncol 2008; 89:141-9. [PMID: 18692928 DOI: 10.1016/j.radonc.2008.06.012] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2008] [Revised: 06/11/2008] [Accepted: 06/19/2008] [Indexed: 11/16/2022]
Abstract
PURPOSE Evaluation of dosimetric benefits of advanced radiotherapy techniques for the treatment of abdominal lesions during early childhood. PATIENTS AND METHODS Treatment planning was performed for five Neuroblastoma (NBL) and four Wilms Tumor (WT) patients. Opposing fields (2F), photon intensity modulated radiotherapy (IMXT) and two proton techniques (passively scattered (PT) and scanned beams (IMPT)) were considered. Averaged dose-volume histograms, associated dosimetric parameters and a radiobiological model for the estimation of the therapy related carcinogenic effect were evaluated. RESULTS With respect to the 2F technique, both proton techniques enabled to reduce mean liver and kidney dose by 40-60%; Organ fractions irradiated at the level of the tolerance dose were reduced by 65% for kidneys and 75% for the liver in NBL patients and by additional 10% for WT patients. IMXT enabled to reduce parameters related to the steep high-dose gradient, e.g., V(15Gy) for the kidneys was reduced by a factor 2-3 compared to 2F. V(12Gy) was reduced by 40% in the liver. On the other side, the improvement of those parameters characterizing the low isodose domain was limited for IMXT. The risk for radiation-induced secondary cancer was doubled for IMXT and even more increased for PT if secondary neutrons were taken into account, while this risk remained the same or was reduced by IMPT with respect to 2F. CONCLUSIONS Proton beams improved all dosimetric parameters for NBL and WT patients compared to photon techniques. This improvement was limited for IMXT mainly to parameters related to the steep high-dose gradient. Further research is needed to minimize uncertainties for secondary cancer estimations.
Collapse
Affiliation(s)
- Martin Hillbrand
- Department of Radiotherapy and Radiobiology, AKH Vienna, Medical University Vienna, Austria.
| | | | | | | | | |
Collapse
|
29
|
Ruben JD, Davis S, Evans C, Jones P, Gagliardi F, Haynes M, Hunter A. The Effect of Intensity-Modulated Radiotherapy on Radiation-Induced Second Malignancies. Int J Radiat Oncol Biol Phys 2008; 70:1530-6. [DOI: 10.1016/j.ijrobp.2007.08.046] [Citation(s) in RCA: 108] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2007] [Revised: 08/26/2007] [Accepted: 08/27/2007] [Indexed: 11/30/2022]
|
30
|
Schneider U, Walsh L. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2008; 47:253-63. [PMID: 18157543 DOI: 10.1007/s00411-007-0151-y] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2006] [Accepted: 12/06/2007] [Indexed: 05/20/2023]
Abstract
Most information on the dose-response of radiation-induced cancer is derived from data on the A-bomb survivors who were exposed to gamma-rays and neutrons. Since, for radiation protection purposes, the dose span of main interest is between 0 and 1 Gy, the analysis of the A-bomb survivors is usually focused on this range. However, estimates of cancer risk for doses above 1 Gy are becoming more important for radiotherapy patients and for long-term manned missions in space research. Therefore in this work, emphasis is placed on doses relevant for radiotherapy with respect to radiation-induced solid cancer. The analysis of the A-bomb survivor's data was extended by including two extra high-dose categories (4-6 Sv and 6-13 Sv) and by an attempted combination with cancer data on patients receiving radiotherapy for Hodgkin's disease. In addition, since there are some recent indications for a high neutron dose contribution, the data were fitted separately for three different values for the relative biological effectiveness (RBE) of the neutrons (10, 35 and 100) and a variable RBE as a function of dose. The data were fitted using a linear, a linear-exponential and a plateau-dose-response relationship. Best agreement was found for the plateau model with a dose-varying RBE. It can be concluded that for doses above 1 Gy there is a tendency for a nonlinear dose-response curve. In addition, there is evidence of a neutron RBE greater than 10 for the A-bomb survivor data. Many problems and uncertainties are involved in combing these two datasets. However, since very little is currently known about the shape of dose-response relationships for radiation-induced cancer in the radiotherapy dose range, this approach could be regarded as a first attempt to acquire more information on this area. The work presented here also provides the first direct evidence that the bending over of the solid cancer excess risk dose response curve for the A-bomb survivors, generally observed above 2 Gy, is due to cell killing effects.
Collapse
Affiliation(s)
- Uwe Schneider
- Division of Medical Physics, Department of Radiation Oncology and Nuclear Medicine, The Triemli Hospital Zürich, 8063 Zürich, Switzerland.
| | | |
Collapse
|
31
|
Schneider U, Lomax A, Besserer J, Pemler P, Lombriser N, Kaser-Hotz B. The Impact of Dose Escalation on Secondary Cancer Risk After Radiotherapy of Prostate Cancer. Int J Radiat Oncol Biol Phys 2007; 68:892-7. [PMID: 17459608 DOI: 10.1016/j.ijrobp.2007.02.029] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2006] [Revised: 02/22/2007] [Accepted: 02/24/2007] [Indexed: 10/23/2022]
Abstract
PURPOSE To estimate secondary cancer risk due to dose escalation in patients treated for prostatic carcinoma with three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated RT (IMRT), and spot-scanned proton RT. METHODS AND MATERIALS The organ equivalent dose (OED) concept with a linear-exponential, a plateau, and a linear dose-response curve was applied to dose distributions of 23 patients who received RT of prostate cancer. Conformal RT was used in 7 patients, 8 patients received IMRT with 6- and 15-MV photons, and 8 patients were treated with spot-scanned protons. We applied target doses ranging from 70 Gy to 100 Gy. Cancer risk was estimated as a function of target dose and tumor control probability. RESULTS At a 100-Gy target dose the secondary cancer risk relative to the 3D treatment plan at 70 Gy was +18.4% (15.0% for a plateau model, 22.3% for a linear model) for the 6-MV IMRT plan, +25.3% (17.0%, 14.1%) for the 15-MV IMRT plan, and -40.7% (-41.3%, -40.0%) for the spot-scanned protons. The increasing risk of developing a radiation-associated malignancy after RT with increasing dose was balanced by the enhanced cure rates at a larger dose. CONCLUSIONS Cancer risk after dose escalation for prostate RT is expected to be equal to or lower than for conventional 3D treatment at 70 Gy, independent of treatment modality or dose-response model. Spot-scanned protons are the treatment of choice for dose escalation because this therapy can halve the risk of secondary cancers.
Collapse
Affiliation(s)
- Uwe Schneider
- Division of Medical Physics, Department of Radiation Oncology and Nuclear Medicine, Triemli Hospital, Zürich, Switzerland.
| | | | | | | | | | | |
Collapse
|